Mammen, A. L., Rajan, A., Pak, K., Lehky, T., Casciola-Rosen, L., Donahue, R. N., . . . Gulley, J. L. (2018). Preexisting anti-acetylcholine receptor autoantibodies and B cell lymphopenia are associated with the development of myositis in thymoma patients treated with avelumab, an immune checkpoint inhibitor targeting programmed death-ligand 1. Ann Rheum Dis.
Chicago Style CitationMammen, Andrew L., et al. "Preexisting Anti-acetylcholine Receptor Autoantibodies and B Cell Lymphopenia Are Associated With the Development of Myositis in Thymoma Patients Treated With Avelumab, an Immune Checkpoint Inhibitor Targeting Programmed Death-ligand 1." Ann Rheum Dis 2018.
Cita MLAMammen, Andrew L., et al. "Preexisting Anti-acetylcholine Receptor Autoantibodies and B Cell Lymphopenia Are Associated With the Development of Myositis in Thymoma Patients Treated With Avelumab, an Immune Checkpoint Inhibitor Targeting Programmed Death-ligand 1." Ann Rheum Dis 2018.